Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | Kidney cancer: combining PARP inhibitors and immunotherapy

Tracy Rose • 13 Feb 2020
GU Cancers 2020
Genitourinary Cancer Kidney Cancer Bempegaldesleukin Sitravatinib

Tracy Rose, MD, MPH, University of North Carolina, Chapel Hill, NC, discusses PARP inhibitors and new immunotherapy agents for metastatic renal cell carcinoma (RCC). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

More from Tracy Rose

Tracy Rose: RCC highlights
1:21
Tracy Rose: RCC highlights
Tracy Rose • 13 Feb 2020
New tools for RCC treatment
1:16
New tools for RCC treatment
Tracy Rose • 14 Feb 2020
Effect of FGFR status on checkpoint inhibitor response in bladder cancer
2:53
Effect of FGFR status on checkpoint inhibitor response in bladder cancer
Tracy Rose • 15 Feb 2019
Non-clear cell kidney cancer trial updates: CALYPSO and KEYNOTE-427
4:10
Non-clear cell kidney cancer trial updates: CALYPSO and KEYNOTE-427
Tracy Rose • 15 Feb 2019

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026
The content of VJOncology is intended for healthcare professionals